At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
AG-013736drug
Likely dose
AG-013736 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PHASE 2 STUDY OF AG-013736 AS SECOND-LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CANCER
In Brief
A Phase 2 clinical trial evaluating AG-013736 for Carcinoma, Renal Cell. Completed, enrolled 64 participants across 18 sites.
Detailed Summary
To investigate objective tumor response of AG-013736 for metastatic Renal Cell Cancer (mRCC)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2007
Enrollment StartDec 2007
Primary CompletionFeb 2010
Study CompletionOct 2012
TodayJul 2026
First PostedDec 10, 2007
Enrollment StartDec 12, 2007
Primary CompletionFeb 26, 2010
Study CompletionOct 30, 2012
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 18.6 years ago
Interventions
AG-013736drug
AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID. Number of cycles: until progression or unacceptable toxicity develops.